ChloroquineV1, PubMed, Checkpoint, bibRecord, 000328

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.

Identifieur interne : 000328 ( PubMed/Checkpoint ); précédent : 000327; suivant : 000329

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.

Auteurs : Rebekah L. Zinn [États-Unis] ; Eric E. Gardner ; Irina Dobromilskaya ; Sara Murphy ; Luigi Marchionni ; Christine L. Hann ; Charles M. Rudin

Source :

Molecular cancer [ 1476-4598 ] ; 2013.

RBID : pubmed:23452820

Descripteurs français

English descriptors

KwdEn :
- Animals, Antineoplastic Combined Chemotherapy Protocols (pharmacology), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Apoptosis (drug effects), Apoptosis Regulatory Proteins (genetics), Apoptosis Regulatory Proteins (metabolism), Autophagy, Beclin-1, Biphenyl Compounds (administration & dosage), Cell Proliferation (drug effects), Cell Survival, Chloroquine (administration & dosage), Drug Resistance, Neoplasm, Female, Gene Knockdown Techniques, Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (metabolism), Lung Neoplasms (pathology), Membrane Proteins (genetics), Membrane Proteins (metabolism), Mice, Mice, Nude, Nitrophenols (administration & dosage), Piperazines (administration & dosage), RNA, Small Interfering (genetics), Small Cell Lung Carcinoma (drug therapy), Small Cell Lung Carcinoma (metabolism), Small Cell Lung Carcinoma (pathology), Sulfonamides (administration & dosage), Tumor Burden (drug effects), Tumor Cells, Cultured, Xenograft Model Antitumor Assays.
MESH :
- chemical , administration & dosage : Biphenyl Compounds, Chloroquine, Nitrophenols, Piperazines, Sulfonamides.
- chemical , genetics : Apoptosis Regulatory Proteins, Membrane Proteins, RNA, Small Interfering.
- drug effects : Apoptosis, Cell Proliferation, Tumor Burden.
- drug therapy : Lung Neoplasms, Small Cell Lung Carcinoma.
- chemical , metabolism : Apoptosis Regulatory Proteins, Lung Neoplasms, Membrane Proteins, Small Cell Lung Carcinoma.
- pathology : Lung Neoplasms, Small Cell Lung Carcinoma.
- pharmacology : Antineoplastic Combined Chemotherapy Protocols.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Animals, Autophagy, Beclin-1, Cell Survival, Drug Resistance, Neoplasm, Female, Gene Knockdown Techniques, Humans, Mice, Mice, Nude, Tumor Cells, Cultured, Xenograft Model Antitumor Assays.

Abstract

New therapies are urgently needed for patients with small cell lung cancer (SCLC). Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. Autophagy can promote survival of cancer cells under stress and comprise a pathway of escape from cytotoxic therapies.

DOI: 10.1186/1476-4598-12-16
PubMed: 23452820

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000341
to stream PubMed, to step Curation: 000341

Links to Exploration step

pubmed:23452820

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.</title>
<author><name sortKey="Zinn, Rebekah L" sort="Zinn, Rebekah L" uniqKey="Zinn R" first="Rebekah L" last="Zinn">Rebekah L. Zinn</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gardner, Eric E" sort="Gardner, Eric E" uniqKey="Gardner E" first="Eric E" last="Gardner">Eric E. Gardner</name>
</author>
<author><name sortKey="Dobromilskaya, Irina" sort="Dobromilskaya, Irina" uniqKey="Dobromilskaya I" first="Irina" last="Dobromilskaya">Irina Dobromilskaya</name>
</author>
<author><name sortKey="Murphy, Sara" sort="Murphy, Sara" uniqKey="Murphy S" first="Sara" last="Murphy">Sara Murphy</name>
</author>
<author><name sortKey="Marchionni, Luigi" sort="Marchionni, Luigi" uniqKey="Marchionni L" first="Luigi" last="Marchionni">Luigi Marchionni</name>
</author>
<author><name sortKey="Hann, Christine L" sort="Hann, Christine L" uniqKey="Hann C" first="Christine L" last="Hann">Christine L. Hann</name>
</author>
<author><name sortKey="Rudin, Charles M" sort="Rudin, Charles M" uniqKey="Rudin C" first="Charles M" last="Rudin">Charles M. Rudin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23452820</idno>
<idno type="pmid">23452820</idno>
<idno type="doi">10.1186/1476-4598-12-16</idno>
<idno type="wicri:Area/PubMed/Corpus">000341</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000341</idno>
<idno type="wicri:Area/PubMed/Curation">000341</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000341</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000328</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000328</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.</title>
<author><name sortKey="Zinn, Rebekah L" sort="Zinn, Rebekah L" uniqKey="Zinn R" first="Rebekah L" last="Zinn">Rebekah L. Zinn</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gardner, Eric E" sort="Gardner, Eric E" uniqKey="Gardner E" first="Eric E" last="Gardner">Eric E. Gardner</name>
</author>
<author><name sortKey="Dobromilskaya, Irina" sort="Dobromilskaya, Irina" uniqKey="Dobromilskaya I" first="Irina" last="Dobromilskaya">Irina Dobromilskaya</name>
</author>
<author><name sortKey="Murphy, Sara" sort="Murphy, Sara" uniqKey="Murphy S" first="Sara" last="Murphy">Sara Murphy</name>
</author>
<author><name sortKey="Marchionni, Luigi" sort="Marchionni, Luigi" uniqKey="Marchionni L" first="Luigi" last="Marchionni">Luigi Marchionni</name>
</author>
<author><name sortKey="Hann, Christine L" sort="Hann, Christine L" uniqKey="Hann C" first="Christine L" last="Hann">Christine L. Hann</name>
</author>
<author><name sortKey="Rudin, Charles M" sort="Rudin, Charles M" uniqKey="Rudin C" first="Charles M" last="Rudin">Charles M. Rudin</name>
</author>
</analytic>
<series><title level="j">Molecular cancer</title>
<idno type="eISSN">1476-4598</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antineoplastic Combined Chemotherapy Protocols (pharmacology)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Apoptosis (drug effects)</term>
<term>Apoptosis Regulatory Proteins (genetics)</term>
<term>Apoptosis Regulatory Proteins (metabolism)</term>
<term>Autophagy</term>
<term>Beclin-1</term>
<term>Biphenyl Compounds (administration & dosage)</term>
<term>Cell Proliferation (drug effects)</term>
<term>Cell Survival</term>
<term>Chloroquine (administration & dosage)</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Gene Knockdown Techniques</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Membrane Proteins (genetics)</term>
<term>Membrane Proteins (metabolism)</term>
<term>Mice</term>
<term>Mice, Nude</term>
<term>Nitrophenols (administration & dosage)</term>
<term>Piperazines (administration & dosage)</term>
<term>RNA, Small Interfering (genetics)</term>
<term>Small Cell Lung Carcinoma (drug therapy)</term>
<term>Small Cell Lung Carcinoma (metabolism)</term>
<term>Small Cell Lung Carcinoma (pathology)</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Tumor Burden (drug effects)</term>
<term>Tumor Cells, Cultured</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Apoptose ()</term>
<term>Autophagie</term>
<term>Bécline-1</term>
<term>Carcinome pulmonaire à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire à petites cellules (métabolisme)</term>
<term>Carcinome pulmonaire à petites cellules (traitement médicamenteux)</term>
<term>Cellules cancéreuses en culture</term>
<term>Charge tumorale ()</term>
<term>Chloroquine (administration et posologie)</term>
<term>Dérivés du biphényle (administration et posologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Nitrophénols (administration et posologie)</term>
<term>Petit ARN interférent (génétique)</term>
<term>Pipérazines (administration et posologie)</term>
<term>Prolifération cellulaire ()</term>
<term>Protocoles de polychimiothérapie antinéoplasique (pharmacologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Protéines membranaires (génétique)</term>
<term>Protéines membranaires (métabolisme)</term>
<term>Protéines régulatrices de l'apoptose (génétique)</term>
<term>Protéines régulatrices de l'apoptose (métabolisme)</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Souris</term>
<term>Souris nude</term>
<term>Sulfonamides (administration et posologie)</term>
<term>Survie cellulaire</term>
<term>Techniques de knock-down de gènes</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Biphenyl Compounds</term>
<term>Chloroquine</term>
<term>Nitrophenols</term>
<term>Piperazines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Apoptosis Regulatory Proteins</term>
<term>Membrane Proteins</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Chloroquine</term>
<term>Dérivés du biphényle</term>
<term>Nitrophénols</term>
<term>Pipérazines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Cell Proliferation</term>
<term>Tumor Burden</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term>
<term>Small Cell Lung Carcinoma</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Petit ARN interférent</term>
<term>Protéines membranaires</term>
<term>Protéines régulatrices de l'apoptose</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Apoptosis Regulatory Proteins</term>
<term>Lung Neoplasms</term>
<term>Membrane Proteins</term>
<term>Small Cell Lung Carcinoma</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome pulmonaire à petites cellules</term>
<term>Protéines membranaires</term>
<term>Protéines régulatrices de l'apoptose</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term>
<term>Small Cell Lung Carcinoma</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Autophagy</term>
<term>Beclin-1</term>
<term>Cell Survival</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Gene Knockdown Techniques</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Nude</term>
<term>Tumor Cells, Cultured</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Apoptose</term>
<term>Autophagie</term>
<term>Bécline-1</term>
<term>Cellules cancéreuses en culture</term>
<term>Charge tumorale</term>
<term>Femelle</term>
<term>Humains</term>
<term>Prolifération cellulaire</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Souris</term>
<term>Souris nude</term>
<term>Survie cellulaire</term>
<term>Techniques de knock-down de gènes</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">New therapies are urgently needed for patients with small cell lung cancer (SCLC). Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. Autophagy can promote survival of cancer cells under stress and comprise a pathway of escape from cytotoxic therapies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23452820</PMID>
<DateCompleted><Year>2013</Year>
<Month>06</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4598</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>12</Volume>
<PubDate><Year>2013</Year>
<Month>Mar</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Molecular cancer</Title>
<ISOAbbreviation>Mol. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.</ArticleTitle>
<Pagination><MedlinePgn>16</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1476-4598-12-16</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">New therapies are urgently needed for patients with small cell lung cancer (SCLC). Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. Autophagy can promote survival of cancer cells under stress and comprise a pathway of escape from cytotoxic therapies.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We explored the combination of ABT-737 and chloroquine, an inhibitor of autophagy, in preclinical models of SCLC. These included cell culture analyses of viability and of autophagic and apoptotic pathway induction, as well as in vivo analyses of efficacy in multiple xenograft models.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Combination treatment of SCLC lines with ABT-737 and chloroquine decreased viability and increased caspase-3 activation over treatment with either single agent. ABT-737 induced several hallmarks of autophagy. However, knockdown of beclin-1, a key regulator of entry into autophagy, diminished the efficacy of ABT-737, suggesting either that the effects of chloroquine were nonspecific or that induction but not completion of autophagy is necessary for the combined effect of ABT-737 and chloroquine. ABT-737 and chloroquine in SCLC cell lines downregulated Mcl-1 and upregulated NOXA, both of which may promote apoptosis. Treatment of tumor-bearing mice demonstrated that chloroquine could enhance ABT-737-mediated tumor growth inhibition against NCI-H209 xenografts, but did not alter ABT-737 response in three primary patient-derived xenograft models.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that although ABT-737 can induce autophagy in SCLC, autophagic inhibition by choroquine does not markedly alter in vivo response to ABT-737 in relevant preclinical models, arguing against this as a treatment strategy for SCLC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zinn</LastName>
<ForeName>Rebekah L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo><Affiliation>Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gardner</LastName>
<ForeName>Eric E</ForeName>
<Initials>EE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dobromilskaya</LastName>
<ForeName>Irina</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Murphy</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marchionni</LastName>
<ForeName>Luigi</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hann</LastName>
<ForeName>Christine L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rudin</LastName>
<ForeName>Charles M</ForeName>
<Initials>CM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA006973</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 CA009243</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>03</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Mol Cancer</MedlineTA>
<NlmUniqueID>101147698</NlmUniqueID>
<ISSNLinking>1476-4598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C501332">ABT-737</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C491997">BECN1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000071186">Beclin-1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009596">Nitrophenols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071186" MajorTopicYN="N">Beclin-1</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009596" MajorTopicYN="N">Nitrophenols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055752" MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>08</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>02</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23452820</ArticleId>
<ArticleId IdType="pii">1476-4598-12-16</ArticleId>
<ArticleId IdType="doi">10.1186/1476-4598-12-16</ArticleId>
<ArticleId IdType="pmc">PMC3599053</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cancer Res. 2001 Jan 15;61(2):439-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11212227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Death Differ. 2004 Apr;11(4):448-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14713959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1994 Jan 1;54(1):6-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8261463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carcinogenesis. 1996 Aug;17(8):1595-607</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8761415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 1998 Mar-Apr;18(2A):1167-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9615783</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Cancer. 1998 Oct;78(8):1035-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9792147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Feb 18;307(5712):1098-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15718470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Jun 2;435(7042):677-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15902208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2005 Sep;5(9):726-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16148885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2005 Sep 23;122(6):927-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16179260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2005 Oct 15-21;366(9494):1385-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16226617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2006 Mar 24;124(6):1283-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16564017</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2007 Feb;117(2):326-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17235397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Death Differ. 2007 Mar;14(3):500-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16990848</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leukemia. 2007 May;21(5):936-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17330103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2007 May 16;26(10):2527-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17446862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2007 Jul-Aug;3(4):374-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17438366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2007 Dec 15;13(24):7271-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Pathol. 2008;3:427-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18039129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2008 Apr 1;68(7):2321-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18381439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Renal Physiol. 2008 Apr;294(4):F777-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18256309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 2009 Mar 1;124(5):1060-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19048625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Surg Oncol. 2009 Mar;16(3):761-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19116755</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2009 Apr 15;69(8):3364-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19351829</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2009 Apr;8(4):883-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19372561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2009 May 28;28(21):2128-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19347031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2009 Sep 1;15(17):5308-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19706824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2009 Dec 25;625(1-3):220-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19836374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2010 Aug 13;285(33):25570-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20529838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Biol Ther. 2011 Jan 15;11(2):127-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21178393</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Biol Ther. 2011 Jan 15;11(2):157-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21228626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2011 Feb 15;17(4):654-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21325294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2011 Mar 1;29(7):909-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21282543</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2011 Sep 15;30(37):3918-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21460857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22237781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2012 Jun;9(6):338-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22508028</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2012 Jun 1;18(11):3163-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22496272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Apoptosis. 2012 Oct;17(10):1050-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22638980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2012 Apr;8(4):445-544</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22966490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Lett. 2012 Jul 28;320(2):171-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22406827</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Dobromilskaya, Irina" sort="Dobromilskaya, Irina" uniqKey="Dobromilskaya I" first="Irina" last="Dobromilskaya">Irina Dobromilskaya</name>
<name sortKey="Gardner, Eric E" sort="Gardner, Eric E" uniqKey="Gardner E" first="Eric E" last="Gardner">Eric E. Gardner</name>
<name sortKey="Hann, Christine L" sort="Hann, Christine L" uniqKey="Hann C" first="Christine L" last="Hann">Christine L. Hann</name>
<name sortKey="Marchionni, Luigi" sort="Marchionni, Luigi" uniqKey="Marchionni L" first="Luigi" last="Marchionni">Luigi Marchionni</name>
<name sortKey="Murphy, Sara" sort="Murphy, Sara" uniqKey="Murphy S" first="Sara" last="Murphy">Sara Murphy</name>
<name sortKey="Rudin, Charles M" sort="Rudin, Charles M" uniqKey="Rudin C" first="Charles M" last="Rudin">Charles M. Rudin</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Zinn, Rebekah L" sort="Zinn, Rebekah L" uniqKey="Zinn R" first="Rebekah L" last="Zinn">Rebekah L. Zinn</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000328 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000328 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:23452820
   |texte=   Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:23452820" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki